PeptidePedia The community reference

MOTS-c: difference between revisions

Diff·revision 13 → 14·21:31, 17 May 2025

Difference between revision 13 and revision 14 of MOTS-c. 3 lines changed; the page grew by 256 bytes.

Revision 13 — 22:48, 2 May 2025
MissedDoseMik (talk)
state which receptor subtype the binding data refers to
3,340 bytes +30
Revision 14 — 21:31, 17 May 2025
MOTSc_Mira (talk)
clarify that the compound is sold as an acetate salt
3,596 bytes +256
7| Status = Not approved; preclinical and early human study7| Status = Not approved; preclinical and early human study
8}}8}}
+9{{medical|talk=Unapproved-compound notice}}
910
10'''MOTS-c''' is a 16-residue peptide encoded within the mitochondrial genome rather than the nuclear genome, and is one of a small group of mitochondria-derived peptides identified since the 2000s. It is not approved for any indication.{{r|lee2015}}11'''MOTS-c''' is a 16-residue peptide encoded within the mitochondrial genome rather than the nuclear genome, and is one of a small group of mitochondria-derived peptides identified since the 2000s. It is not approved for any indication.{{r|lee2015}}
2526
26In humans, exercise increases circulating MOTS-c, and lower concentrations have been associated with obesity and insulin resistance in cross-sectional studies. Association of that kind cannot establish direction: lower concentrations may contribute to the phenotype or result from it.{{r|kim2018}}27In humans, exercise increases circulating MOTS-c, and lower concentrations have been associated with obesity and insulin resistance in cross-sectional studies. Association of that kind cannot establish direction: lower concentrations may contribute to the phenotype or result from it.{{r|kim2018}}
+28
+29No adequately powered controlled trial of administration in humans has reported. The gap between the preclinical literature and the human evidence is wide, and it should not be closed by inference.{{r|lee2015}}
2730
28== References ==31== References ==